8-K filed August 19, 2024, 7:59 PM ET ticker COYA CIK 0001835022

leadership confidence high sentiment neutral materiality 0.60

Coya Therapeutics promotes Arun Swaminathan to CEO effective Nov 1, 2024; Howard Berman becomes Executive Chairman

Coya Therapeutics, Inc.

Arun Swaminathan, current CBO, promoted to CEO effective Nov 1, 2024; succeeds Howard Berman.
Howard Berman resigns as CEO effective Oct 31, 2024, remains as Executive Chairman and director.
Swaminathan appointed to Board of Directors as Class III director effective immediately.
Swaminathan led Dr. Reddy's licensing transaction worth up to $700M; executed over $6B in deals.
Company expects upcoming Alzheimer's data at CTAD24 on Oct 29, 2024; continues progress on COYA 302 in ALS.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Howard Berman

Chief Executive Officer

COYA · Coya Therapeutics, Inc.

Effective: 2024-10-31
Successor: Arun Swaminathan
Filed: August 19, 2024, 7:59 PM ET

Dr. Howard Berman, who, on August 16, 2024, notified the Company that he would be resigning as Chief Executive Officer of the Company effective at the close of business on October 31, 2024.

Role change

Arun Swaminathan

Chief Executive Officer

COYA · Coya Therapeutics, Inc.

Effective: 2024-11-01
Filed: August 19, 2024, 7:59 PM ET

Arun Swaminathan, the Company’s Chief Business Officer since April 2023, will serve as Chief Executive Officer of the Company.

Appointed

Arun Swaminathan

Director

COYA · Coya Therapeutics, Inc.

Effective: 2024-08-19
Filed: August 19, 2024, 7:59 PM ET

Dr. Swaminathan was also appointed to the Company’s Board as a Class III director to serve until the Company’s 2025 annual meeting of stockholders

Appointed

Howard Berman

Executive Chairman

COYA · Coya Therapeutics, Inc.

Effective: 2024-11-01
Filed: August 19, 2024, 7:59 PM ET

After his resignation, Dr. Berman intends to remain a member of the Company’s board of directors (the “Board”) and serve as Executive Chairman of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Howard Berman resigned as Chief Executive Officer at Coya Therapeutics, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

Dr. Howard Berman, who, on August 16, 2024, notified the Company that he would be resigning as Chief Executive Officer of the Company effective at the close of business on October 31, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Arun Swaminathan was appointed as Chief Executive Officer at Coya Therapeutics, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Arun Swaminathan, the Company’s Chief Business Officer since April 2023, will serve as Chief Executive Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Arun Swaminathan was appointed as Director at Coya Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

Dr. Swaminathan was also appointed to the Company’s Board as a Class III director to serve until the Company’s 2025 annual meeting of stockholders

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Howard Berman was appointed as Executive Chairman at Coya Therapeutics, Inc..

Action: appointed
Role: Executive Chairman

Exact text from the filing

After his resignation, Dr. Berman intends to remain a member of the Company’s board of directors (the “Board”) and serve as Executive Chairman of the Board.

View on SEC.gov

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-202551

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.